KR100794891B1 - 씨디피-콜린 또는 그의 약학적으로 수용 가능한 염을 포함하는 알코올 금단 증후군의 치료용 약제 및 치료 방법 - Google Patents

씨디피-콜린 또는 그의 약학적으로 수용 가능한 염을 포함하는 알코올 금단 증후군의 치료용 약제 및 치료 방법 Download PDF

Info

Publication number
KR100794891B1
KR100794891B1 KR1020027012966A KR20027012966A KR100794891B1 KR 100794891 B1 KR100794891 B1 KR 100794891B1 KR 1020027012966 A KR1020027012966 A KR 1020027012966A KR 20027012966 A KR20027012966 A KR 20027012966A KR 100794891 B1 KR100794891 B1 KR 100794891B1
Authority
KR
South Korea
Prior art keywords
acid
choline
treatment
alcohol withdrawal
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020027012966A
Other languages
English (en)
Korean (ko)
Other versions
KR20030005248A (ko
Inventor
라파엘 포오구에트
조지 라멘톨
라파엘 로자노
줄리안 아구트
제수스 토레스
마누엘 엠. 라가
조셉 엠. 카스텔로
조세 에이. 오르티즈
Original Assignee
페레르 인터내쇼날 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 페레르 인터내쇼날 에스.에이. filed Critical 페레르 인터내쇼날 에스.에이.
Publication of KR20030005248A publication Critical patent/KR20030005248A/ko
Application granted granted Critical
Publication of KR100794891B1 publication Critical patent/KR100794891B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020027012966A 2000-03-29 2001-03-28 씨디피-콜린 또는 그의 약학적으로 수용 가능한 염을 포함하는 알코올 금단 증후군의 치료용 약제 및 치료 방법 Expired - Fee Related KR100794891B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP200000765 2000-03-29
ES200000765A ES2170649B1 (es) 2000-03-29 2000-03-29 Uso de la cdp-colina en el tratamiento de la abstinencia alcoholica.
PCT/EP2001/003536 WO2001072288A2 (en) 2000-03-29 2001-03-28 Use of cdp-choline for the treatment of alcohol withdrawal syndrome

Publications (2)

Publication Number Publication Date
KR20030005248A KR20030005248A (ko) 2003-01-17
KR100794891B1 true KR100794891B1 (ko) 2008-01-14

Family

ID=8492914

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027012966A Expired - Fee Related KR100794891B1 (ko) 2000-03-29 2001-03-28 씨디피-콜린 또는 그의 약학적으로 수용 가능한 염을 포함하는 알코올 금단 증후군의 치료용 약제 및 치료 방법

Country Status (21)

Country Link
US (1) US6894032B2 (enExample)
EP (1) EP1267892B1 (enExample)
JP (1) JP4724348B2 (enExample)
KR (1) KR100794891B1 (enExample)
AT (1) ATE281172T1 (enExample)
AU (2) AU2001262141B2 (enExample)
BR (1) BR0109477A (enExample)
CA (1) CA2402707C (enExample)
CZ (1) CZ298933B6 (enExample)
DE (1) DE60106890T2 (enExample)
DK (1) DK1267892T3 (enExample)
ES (1) ES2170649B1 (enExample)
IL (2) IL151163A0 (enExample)
MX (1) MXPA02009442A (enExample)
NO (1) NO329766B1 (enExample)
NZ (1) NZ520825A (enExample)
PL (1) PL199291B1 (enExample)
PT (1) PT1267892E (enExample)
RU (1) RU2251422C2 (enExample)
WO (1) WO2001072288A2 (enExample)
ZA (1) ZA200206349B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8030294B2 (en) 2000-03-16 2011-10-04 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
EP1541154A1 (en) * 2002-07-11 2005-06-15 Yamasa Corporation Medicinal composition for drug-induced neuropathy
CN100430066C (zh) 2002-11-08 2008-11-05 麦克莱恩医院 用于烟草依赖性和戒断治疗的化合物
AU2003299715A1 (en) * 2002-12-20 2004-07-22 The Mclean Hospital Corporation Compounds for the normalization of the sleep/wake cycle
US20050129710A1 (en) * 2003-10-08 2005-06-16 Renshaw Perry F. Methods of treating psychiatric substance abuse, and other disorders using combinations containing omega-3 fatty acids
EP1765075A4 (en) 2004-06-10 2010-11-10 Mclean Hospital Corp PYRIMIDINES, AS FORM. uridine; IN THE TREATMENT OF PATIENTS WITH MANIC-DEPRESSIVE PSYCHOSIS
WO2006020703A1 (en) 2004-08-11 2006-02-23 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960706341A (ko) * 1993-12-10 1996-12-09 플랭크 베커· 베르너 웨스링 유기 인 콜린스테라아제 억제제에 의해 야기되는 중독의 예방 및 예비 치료를 위한 약제 제형(pharmaceutical formulation for preventing or pre-treating poisoning by organophosphoric cholinesterase inhibitors)
KR19990000142A (ko) * 1997-06-03 1999-01-15 맹섭 골프채의 헤드커버
WO1999007385A1 (en) * 1997-08-08 1999-02-18 The Mclean Hospital Corporation Use of cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308627A (en) * 1990-08-07 1994-05-03 Umbdenstock Jr Anthony J Nutritional supplement for optimizing cellular health
RU2072239C1 (ru) * 1991-01-11 1997-01-27 Институт биохимии СО РАМН Способ коррекции метаболической зависимости от алкоголя и средство л.е.панина для его осуществления
CA2193967C (en) * 1994-07-01 2007-09-11 Reid W. Von Borstel Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
RU2127589C1 (ru) * 1997-06-03 1999-03-20 Порембский Ярослав Олегович Способ лечения стрессорных поражений нервной системы
US8030294B2 (en) 2000-03-16 2011-10-04 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960706341A (ko) * 1993-12-10 1996-12-09 플랭크 베커· 베르너 웨스링 유기 인 콜린스테라아제 억제제에 의해 야기되는 중독의 예방 및 예비 치료를 위한 약제 제형(pharmaceutical formulation for preventing or pre-treating poisoning by organophosphoric cholinesterase inhibitors)
KR19990000142A (ko) * 1997-06-03 1999-01-15 맹섭 골프채의 헤드커버
WO1999007385A1 (en) * 1997-08-08 1999-02-18 The Mclean Hospital Corporation Use of cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Psychopharmacology (Renshaw et al., vol. 142:132-138, 1999) *
Psychopharmacology(Renshaw et al., 1999, vol.142:132-138) *
국제특허공보 99/07385
한국특허공개공보 제10-1996-0706341호

Also Published As

Publication number Publication date
DK1267892T3 (da) 2005-03-07
EP1267892B1 (en) 2004-11-03
NO20024574L (no) 2002-11-22
ES2170649A1 (es) 2002-08-01
ATE281172T1 (de) 2004-11-15
WO2001072288A3 (en) 2002-05-10
EP1267892A2 (en) 2003-01-02
MXPA02009442A (es) 2003-02-12
PT1267892E (pt) 2005-03-31
US6894032B2 (en) 2005-05-17
CZ298933B6 (cs) 2008-03-12
NZ520825A (en) 2004-04-30
BR0109477A (pt) 2003-06-03
KR20030005248A (ko) 2003-01-17
PL199291B1 (pl) 2008-09-30
AU6214101A (en) 2001-10-08
DE60106890T2 (de) 2005-11-03
NO329766B1 (no) 2010-12-13
PL363177A1 (en) 2004-11-15
ZA200206349B (en) 2003-08-08
WO2001072288A2 (en) 2001-10-04
US20030162749A1 (en) 2003-08-28
CA2402707A1 (en) 2001-10-04
ES2170649B1 (es) 2003-06-16
NO20024574D0 (no) 2002-09-24
IL151163A0 (en) 2003-04-10
JP4724348B2 (ja) 2011-07-13
RU2002129579A (ru) 2004-03-27
RU2251422C2 (ru) 2005-05-10
DE60106890D1 (de) 2004-12-09
AU2001262141B2 (en) 2005-03-10
CZ20023245A3 (cs) 2003-03-12
IL151163A (en) 2011-01-31
JP2003528133A (ja) 2003-09-24
CA2402707C (en) 2007-11-13

Similar Documents

Publication Publication Date Title
AU725249B2 (en) Use of a thienotriazolodiazepine to increase apolipoprotein A-I levels
Stuppaeck et al. Carbamazepine versus oxazepam in the treatment of alcohol withdrawal: a double-blind study
US8492350B2 (en) Therapeutic agent for pain disease
KR100794891B1 (ko) 씨디피-콜린 또는 그의 약학적으로 수용 가능한 염을 포함하는 알코올 금단 증후군의 치료용 약제 및 치료 방법
KR100481188B1 (ko) 글루타민산염관련질환치료용알카노일-l-카르니틴의용도
US20050176675A1 (en) Stable and active complexes of adenosine and adenosine phosphates with aminoalcohols for the treatment of pulmonary artery hypertension, cardiac failure and other diseases
US9555055B2 (en) Use of albiflorin and metabolites thereof
WO2018113027A1 (zh) 白果内酯作为增效剂在制备防治脑神经损伤性疾病药物的应用
JP3942207B2 (ja) うつ性症状改善剤
ITRM970594A1 (it) Associazione di l-carnitina e alcanoil l-carnitine per il trattamento dell'alcoolismo
CN103599115B (zh) 一种组合物在制备抗癫痫药物中的应用
CN111184731A (zh) 人参皂苷Rg5在制备用于改善睡眠的药物组合物中的用途
US6489356B2 (en) Method for treating pain in humans
US20220211708A1 (en) Pharmaceutical combination of pimozide and methotrexate and use thereof
CN107737103B (zh) 一种用于治疗横纹肌肉瘤的瘤内注射液
ITRM990315A1 (it) Composizione per la prevenzione ed il trattamento delle alterazioni mentali e comportamentali.
ITMI981037A1 (it) Uso di l-aspartato di potassio e di magnesio per aumentare la concentrazione ematica di glutammina
MXPA97005856A (en) Use of melatonine in the manufacture of unmedicament to deal with addiction to dro

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 5

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20121226

Year of fee payment: 6

PR1001 Payment of annual fee

Fee payment year number: 6

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20131224

Year of fee payment: 7

PR1001 Payment of annual fee

Fee payment year number: 7

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20141222

Year of fee payment: 8

PR1001 Payment of annual fee

Fee payment year number: 8

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20151224

Year of fee payment: 9

PR1001 Payment of annual fee

Fee payment year number: 9

St.27 status event code: A-4-4-U10-U11-oth-PR1001

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Not in force date: 20170109

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20170109

St.27 status event code: N-4-6-H10-H13-oth-PC1903

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000